文献速递头颈部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

头颈癌寡转移SABR试验中质量保证与生存的关系

Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-24

该研究基于GORTEC 2014-04 OMET随机2期试验,通过个体病例审查评估头颈癌寡转移患者SABR方案偏离对生存和局部控制的影响。69例患者(98个转移灶)中,无偏离、轻微偏离和严重偏离患者的中位总生存分别为61.7、50.9和20.9个月,严重偏离与更差生存相关。

要点

  • 严重方案偏离患者中位总生存仅20.9个月,显著差于无偏离者的61.7个月
  • 严重偏离主要与寡转移灶累积大小和危及器官邻近相关
  • 偏离在试验组间分布均衡,但严重偏离者适形数和改良梯度指数更偏离最优值

核心结论

  • 个体病例审查发现的方案偏离在试验组间均匀分布,严重偏离与更差生存相关。

研究设计与样本

  • 基于GORTEC 2014-04 OMET随机2期试验的探索性分析,纳入69例患者共98个寡转移灶。

主要发现

  • 无偏离患者(N=19)中位总生存61.7个月(IQR 41.1-未达到)。
  • 至少轻微偏离患者(N=36)中位总生存50.9个月(IQR 32.1-未达到)。
  • 至少严重偏离患者(N=12)中位总生存20.9个月(IQR 12.1-81.7)。
  • 严重偏离患者中适形数(P < .001)和改良梯度指数(P = .01)更偏离最优值。

关键数值与推荐

  • 个体病例审查评估寡转移拓扑复杂性、适应证、勾画(靶区、危及器官)、图像引导、处方、靶区覆盖和危及器官剂量。

临床怎么用

  • 头颈癌寡转移SABR应加强质量保证,个体病例审查可识别严重偏离并可能改善生存。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The OMET GORTEC 2014-04 trial showed prolonged survival with multisite Stereotactic Ablative Body Radiation therapy (SABR) in patients with oligometastatic head and neck cancer. However, deviations from radiation therapy protocol can be a confounding factor in clinical trials. The impact of SABR quality assurance by individual case review (ICR) of protocol deviations and quality metrics on survival and local control at SABR-treated oligometastases was assessed. METHODS AND MATERIALS: The SABR planning and delivery protocol was standardized based on the oligometastasis number/size/nearby critical structures (organs at risk [OARs]) across SABR techniques. ICR assessed oligometastatic topological complexity, indication, delineation (targets, OARs), image guidance, prescription, target coverage, and OAR doses. An exploratory analysis of quantitative dosimetric indices was also performed. RESULTS: Among 69 patients (98 metastases, unique 58.0%, lung-only 82.6%), there was no imbalance of deviations between the trial arms. Median follow-up was 55.3 months. Median overall survival was 61.7 months (IQR, 41.1-Not reached) in patients (N = 19) without deviation, 50.9 months (IQR, 32.1-Not reached) in patients (N = 36) with at least a minor deviation, and 20.9 months (IQR, 12.1-81.7) in those (N = 12) with at least a major deviation. Among patients with a major deviation, the conformity number (P < .001) and modified gradient index (P = .01) deviated more from their optimal values. CONCLUSIONS: Deviations from protocol by ICR were evenly distributed between arms. Major deviations were mostly related to the cumulative size of the oligometastases and OAR proximity and were associated with poorer survival in this SABR trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Maury P, Sayous Y, Marnaoui R, et al. Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40714135. doi:10.1016/j.ijrobp.2025.07.1422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。